The microbiome and its role in human health represents a paradigm shift in how medicines will be developed. The Pharmabiotic Research Institute (PRI) was founded to make Microbiotic Medicinal Products a therapeutic reality in Europe. The PRI, as a neutral and financially independent non-profit association, applies a unique collaborative approach to improve market access and provide technical and regulatory intelligence for its members. PRI members have a stake in regulatory, technical and collaboration efforts of the microbiome & human health space.
For NIZO this means an unique possibility to transfer knowledge and experience with other companies and research institutes in the microbiome and clinical area, like the Clinical Studies Task Group.